Overview

Sourcing the E1L3N clone for PD-L1 immunohistochemistry centers on a rabbit monoclonal antibody from Cell Signaling Technology that is labeled for research use only. Because validated companion assays can be expensive and are not available in every laboratory, many reference labs build a lab-developed test around E1L3N on an automated stainer to estimate PD-L1 expression. Published comparisons report high concordance between E1L3N and the 22C3 and SP263 assays at a 50 percent tumor proportion score cutoff, which is why the clone attracts interest where budget or platform access limits standardized kits. The procurement conversation is therefore less about buying a finished diagnostic and more about securing a validated antibody and the reagents needed to run it reproducibly.

Antibody Validation Workflow

A lab-developed PD-L1 test must be analytically validated before reporting patient results. That means confirming the staining protocol, establishing the scoring method, and checking concordance against a reference assay on local tissue. E1L3N is typically run on a Ventana platform, and the published protocol uses heat-induced epitope retrieval followed by incubation with the antibody and a detection system. Buyers should ask for the clone identity, the intended use statement, and any validation data the supplier can share, because research-use-only status places the validation burden on the performing laboratory rather than the reagent vendor.

Sourcing and Supply Considerations

When evaluating a supplier, confirm lot-to-lot consistency and the availability of the full staining line, not just the primary antibody. Temperature-controlled shipping and clear storage guidance protect reagent performance during transit. Because the clone is research use only, purchasing agreements should state that the material is not represented as an approved companion diagnostic. Laboratories then document their own standard operating procedure, internal quality controls, and proficiency testing so the service meets the expectations of pathologists who will read the slides and of the clinicians who act on the score. A practical sourcing plan also tracks expiry dates and minimum stock levels, so that routine PD-L1 requests are never delayed by a back-ordered reagent during high-demand periods.

FAQ

Q: Is E1L3N an FDA-approved companion diagnostic? A: No. E1L3N is a research-use-only antibody; any clinical use must be through a laboratory's own validated, lab-developed test rather than a pre-approved kit.

Q: Which platform is E1L3N usually run on? A: Studies commonly run E1L3N on Ventana automated stainers, though the clone can be adapted to multiple platforms with local validation.

Q: How does E1L3N compare with 22C3 and SP263? A: Comparative studies report strong concordance with both at a 50 percent cutoff, with 100 percent sensitivity reported for E1L3N against each at that threshold.